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Chimpanzees in west central Africa (Pan troglodytes troglodytes) are endemically 39 
infected with simian immunodeficiency viruses (SIVcpzPtt) that have crossed the species barrier 40 
to humans and gorillas on at least five occasions, generating pandemic and non-pandemic 41 
forms of human immunodeficiency virus type 1 (HIV-1) as well as SIVgor. Chimpanzees in east 42 
Africa (P. t. schweinfurthii) are also infected with SIVcpz; however, their viruses (SIVcpzPts) 43 
have never been found in humans.  To examine whether the latter is due to a paucity of natural 44 
infections, we used non-invasive methods to screen wild-living eastern chimpanzees in the 45 
Democratic Republic of the Congo (DRC), Uganda and Rwanda.  We also screened bonobos 46 
(Pan paniscus) in the DRC, a species not previously tested for SIV in the wild. Fecal samples 47 
(n=3,108) were collected at 50 field sites, tested for species and subspecies origin, and 48 
screened for SIVcpz antibodies and nucleic acids. Of 2,565 samples from eastern chimpanzees, 49 
323 were antibody positive and 92 contained viral RNA. The antibody positive samples 50 
represented 76 individuals from 19 field sites, all sampled north of the Congo River in an area 51 
spanning 250,000 km2. In this region, SIVcpzPts was common and widespread, with seven field 52 
sites exhibiting infection rates of 30% or greater.  The overall prevalence of SIVcpzPts infection 53 
was 13.4% (95% CI 10.7% - 16.5%).  In contrast, none of 543 bonobo samples from six sites 54 
was antibody positive. All newly identified SIVcpzPts strains clustered in strict accordance to 55 
their subspecies origin; however, they exhibited considerable genetic diversity, especially in 56 
protein domains known to be under strong host selection pressure. Thus, the absence of 57 
SIVcpzPts zoonoses cannot be explained by an insufficient primate reservoir.  Instead, greater 58 
adaptive hurdles may have prevented the successful colonization of humans by P. t. 59 





Of over 40 African primate species naturally infected with simian immunodeficiency 63 
viruses (SIVs), chimpanzees (Pan troglodytes) are unique because they harbor the virus 64 
(SIVcpz) that spawned the human AIDS pandemic (20, 30, 78).  It is now well established that 65 
chimpanzees are the original source of viruses currently found in chimpanzees, gorillas and 66 
humans, and that ape viruses have been transmitted to humans on at least four occasions, 67 
generating human immunodeficiency virus type 1 (HIV-1) groups M, N, O and P (24, 65, 66).  68 
Chimpanzees also differ from most other primate species by having acquired their infection 69 
relatively more recently, as a consequence of cross-species transmission and recombination of 70 
viruses infecting monkeys on which they prey (3).  Importantly, natural history studies have 71 
shown that SIVcpz is quite pathogenic and has a substantial negative impact on the health, 72 
reproduction and life span of its natural host (17, 29, 55, 75).  Thus, in addition to representing a 73 
potential source for human infection, SIVcpz also comprises a serious threat to chimpanzee 74 
populations living in the wild (55).    75 
Chimpanzees are highly endangered, thus requiring non-invasive approaches to study 76 
SIVcpz infection in wild populations (60, 61). To address this, we have -- over the past decade -- 77 
developed approaches that permit the detection of virus specific antibodies and nucleic acids in 78 
fecal and urine samples (29, 30, 36, 42, 55, 56, 59, 60, 73, 74, 78, 79, 85).  Examining the 79 
molecular epidemiology of SIVcpz in the wild, we found that only two of the four currently 80 
recognized subspecies (9), i.e., central (P. t. troglodytes) and eastern (P. t. schweinfurthii) 81 
chimpanzees, but not western (P. t. verus) and Nigeria-Cameroonian (P. t. ellioti) chimpanzees, 82 
are naturally infected by SIVcpz (30, 35, 56, 59, 60, 78). We also found that SIVcpz is unevenly 83 
distributed among wild apes, with high prevalence rates (up to 50%) in some communities, and 84 
rare or absent infection in others (29, 30, 55, 56, 60, 78).  Molecular studies of existing SIVcpz 85 
strains revealed that they cluster in accordance to their subspecies origin in two highly divergent 86 
 
 
lineages, termed SIVcpzPtt and SIVcpzPts (66).  Interestingly, all groups of HIV-1 as well as 87 
viruses (SIVgor) from western gorillas (Gorilla gorilla gorilla) fall into just one of these lineages, 88 
clustering with SIVcpzPtt from P. t. troglodytes, implicating the central subspecies as the source 89 
of both human and gorilla infections (30, 66, 73, 79).  In contrast, evidence for transmission of 90 
SIVcpzPts strains to either humans or sympatric eastern gorillas (G. g. beringei) is lacking (42), 91 
raising questions as to the relative abundance and distribution of SIVcpz in wild-living P. t. 92 
schweinfurthii populations (46). 93 
Eastern chimpanzees live in central and east Africa (Fig. 1A), in an area that ranges 94 
from the southeastern parts of the Central African Republic (CAR) through the northern parts of 95 
the Democratic Republic of Congo (DRC), to southwestern Sudan and the western parts of 96 
Uganda, Rwanda, Burundi and Tanzania (51).  The first SIVcpzPts strain (ANT) was identified in 97 
an ape captured at an unknown location in the DRC and exported to Belgium (45, 80, 20).  98 
Subsequent testing of fecal samples from a limited number of chimpanzees in the vicinity of 99 
Kisangani indicated that SIVcpzPts was also present in wild-living P. t. schweinfurthii 100 
communities in the DRC (85). However, extensive field studies in east Africa revealed a 101 
surprising paucity of SIVcpzPts infections. Although infected chimpanzees were identified in 102 
Gombe National Park (29, 55, 60, 61) and the Ugalla region of western Tanzania (56), 103 
communities in the Budongo Forest (BG) in northern Uganda, the Kibale National Park (KB) in 104 
western Uganda, the Bwindi Impenetrable Forest (BW) in southern Uganda, and Mahale 105 
Mountains National Park (MH) in Tanzania seemed free of SIVcpz infection (56, 60, 67).  106 
Moreover, none of over 300 fecal samples from the Nyungwe Forest Reserve (NY) in western 107 
Rwanda was virus positive (67). Thus, in contrast to the high infection rates observed for P. t. 108 
troglodytes apes in southern Cameron (30, 42, 78) and northern Gabon (36), field studies at the 109 
eastern limits of the P. t. schweinfurthii range identified only isolated foci of infection.   110 
The habitat of eastern chimpanzees in Uganda, Rwanda and Tanzania is severely 111 
fragmented (Fig. 1B), due to extensive deforestation, expanding agriculture and human 112 
 
 
encroachment (51). To test whether this habitat loss might have contributed to the paucity of 113 
SIVcpzPts infection in east Africa, we targeted wild-living apes in the Democratic Republic of the 114 
Congo, a country that is home to half of the world’s remaining chimpanzees (10, 51). There are 115 
two different chimpanzee species in the DRC, the eastern chimpanzee (Pan troglodytes 116 
schweinfurthii) and the bonobo (Pan paniscus), who live in non-overlapping ranges north and 117 
south of the Congo River, respectively (Fig. 1A).  Current population estimates suggest that 118 
there may be as many as 180,000 to 200,000 eastern chimpanzees and 30,000 to 50,000 119 
bonobos still remaining in largely intact forest blocks (10, 19, 51). With the exception of one 120 
study (85), wild-living apes in the DRC have not previously been surveyed for SIV. Here, we 121 
show that eastern chimpanzees, but not bonobos, are widely and commonly infected with 122 
SIVcpzPts and thus represent a substantial virus reservoir.  123 
 124 
MATERIALS AND METHODS 125 
 126 
Study sites and sample collection.  The vast majority of ape fecal samples were 127 
collected in the DRC from non-habituated eastern chimpanzees (n=2,480) and bonobos (n=543) 128 
by teams of local trackers (Table 1). Samples were collected in the vicinity of chimpanzee night 129 
nests or when encountered during forest walks, placed into 50 ml conical tubes, and preserved 130 
in an equal volume of RNAlater (Life Technologies) as described (30, 60, 78).  Tubes were 131 
labeled with a sample number, the field site code, and GPS coordinates when available.  132 
Because local trackers were participating in the collection effort, the quality of samples varied 133 
between field sites and individual specimens were frequently divided into multiple aliquots 134 
without this being indicated. In four instances, samples were collected from pet chimpanzees 135 
kept by local villagers (BU203, KS133, KS134 and KS135). Samples were also collected from 136 
habituated chimpanzee communities in the Budongo Reserve (BG) in northern Uganda (n=20) 137 
(53) and the Kyambura Gorge (KY) in western Uganda (n=16) (32).  At the latter two sites, fecal 138 
 
 
samples were collected from individually known apes under direct observation by resident 139 
primatologists. Finally, samples were obtained from non-habituated chimpanzees in the 140 
Gishwati Forest (GI) in northwestern Rwanda (n=49) (12, 50).  Because of a lack of refrigeration 141 
at most field sites, especially in the DRC, samples were kept at ambient temperature for varying 142 
periods of time (usually several weeks, but in some instances several months) before they could 143 
be stored at -20°C.  In the DRC, this was done at a central laboratory in Kisangani, where 144 
samples were then batched and shipped to the US.  Bonobo samples from the ML field site 145 
were stored at -80°C at the Institut National de Recherche Biomédicale in Kinshasa and then 146 
shipped directly to the University of Montpellier.   147 
 148 
SIVcpz antibody detection.  All fecal samples were screened for the presence of HIV-1 149 
cross-reactive antibodies as previously described (30, 42, 60, 78). Bonobo samples from the ML 150 
field site were tested using the INNO-LIA HIV I/II Score Confirmation test (Innogenetics, Ghent, 151 
Belgium) (78). All other samples were examined by enhanced chemiluminescent Western 152 
immunoblot analysis modified for RNAlater preserved specimens.  RNAlater is a high salt 153 
solution (25 mM sodium citrate, 10 mM EDTA, 70 g ammonium sulfate/100 ml solution, pH 5.2) 154 
that preserves nucleic acids, but precipitates proteins, including immunoglobulin.  To prepare 155 
extracts suitable for Western blot analysis, fecal/RNAlater mixtures (1.5 ml) were diluted with 156 
PBS-Tween-20 (8.5 ml), inactivated for 1 hr at 60ºC, clarified by centrifugation (3500 x g for 30 157 
min) to remove solid debris, and then dialyzed against PBS overnight at 4ºC to reconstitute 158 
fecal immunoglobulin.  Reconstituted extracts were subjected to immunoblot analysis using 159 
commercially available HIV-1 antigen containing strips (Maxim Biomedical, Inc.).  Sample 160 
integrity was examined using an IgG control. 161 
 162 
Amplification of SIVcpz virion RNA.  All Western blot positive samples were tested for 163 
the presence of SIV nucleic acids by reverse-transcription polymerase chain reaction (RT-PCR) 164 
 
 
amplification as described (30, 38, 42, 60, 78).  Briefly, fecal RNA was extracted using the 165 
RNAqueous Midi Kit (Life Technologies) and subjected to RT-PCR amplification using SIVcpz 166 
specific gag, pol, vpu, gp41, and gp41/nef consensus primers (Table S1).  PCR conditions 167 
generally included 60 cycles of denaturation (94 °C, 20 s), annealing (50 °C, 30 s), and 168 
elongation (68 °C, 1.5 min) for the first round.  Second round conditions included 50 cycles of 169 
denaturation (94 °C, 20 s), annealing (52 °C, 30 s), and elongation (68 °C, 1 min). All amplicons 170 
were gel purified and sequenced directly.  Samples that failed to yield SIVcpz amplicons were 171 
re-amplified using pan-SIV specific primers (Table S1), so as to not miss infection with SIVs 172 
other than SIVcpz.  173 
 174 
Individual identification.  All fecal samples were subjected to mitochondrial DNA 175 
analysis to confirm their species and subspecies origin.  In addition, all antibody positive P. t. 176 
schweinfurthii samples as well as 146 bonobo samples from three different field sites (IK, LK, 177 
KR) were subjected to microsatellite analyses.  Fecal DNA was extracted as described, and 178 
used to amplify a 498 bp fragment of the mitochondrial D-loop region (30, 39, 60).  Amplicons 179 
were sequenced directly (using one primer which yielded 479 bp of sequence) and classified 180 
into distinct mitochondrial haplotypes (Fig. S1; Table S2).  To identify the number of sampled 181 
individuals, fecal samples were genotyped at four (P. t. schweinfurthii) or eight (P. paniscus) 182 
autosomal microsatellite loci (Tables S3 and S4), with amplification products sized on an 183 
automated sequencer using GeneMapper 4.0 (Applied Biosystems).  Samples were first 184 
grouped by field site and mitochondrial DNA haplotype. Within each haplotype, samples were 185 
then grouped by microsatellite genotypes, and when possible also by gender and viral genotype. 186 
Due to prolonged storage at ambient temperatures, even mtDNA positive samples were 187 
frequently partially degraded. We thus allowed allelic mismatches at up to four (eastern 188 
chimpanzees) or six (bonobos) loci, if other markers (mtDNA haplotype, gender) indicated 189 
possible identity.  This very conservative approach likely resulted in an underestimation of the 190 
 
 
number of sampled individuals. Samples with evidence of DNA admixture (multiple peaks for 191 
the same locus or double peaks in the mtDNA sequence) were excluded.  192 
 193 
Gender determination.  For most samples, gender was determined by amplifying a 194 
218-bp fragment of the amelogenin gene that contains a 6-bp insertion in the Y, but not the X 195 
chromosome, using primers AMEL-F212 (5'-ACCTCATCCTGGGCACCCTGG-3') and AMEL-196 
R212 (5'-AGGCTTGAGGCCAACCATCAG-3') (70). PCR conditions were the same as for the 197 
microsatellite analyses and fragments were sized on an automated sequencer. For samples that 198 
failed this genotyping, a second set of amelogenin primers (AMXY-1F 5’-199 
CTGATGGTTGGCCTCAAGCCTGTG-3’ and AMXY-2R 5’-TAAAGAGATTCATTAACTTGACTG-200 
3’) were used to amplify a 977-bp fragment from the X chromosome and a 788-bp fragment 201 
from the Y chromosome. The resulting PCR products were sized by 1.2% agarose gel 202 
electrophoresis (16, 60). 203 
 204 
SIVcpz prevalence determination. The prevalence of SIVcpz infection was estimated 205 
for each field site based on the proportion of SIVcpz antibody positive fecal samples, but 206 
correcting for degradation and redundant sampling.  As shown in Table 1, 19% of eastern 207 
chimpanzee and 9% bonobo fecal samples failed to yield usable mtDNA sequences and were 208 
thus excluded from further analysis. A subset of the remainder was then subjected to 209 
microsatellite analyses, which provided a quantitative estimate of oversampling for both species.  210 
For P. t. schweinfurthii, genotyping of 323 antibody positive fecal samples from 19 field sites 211 
identified 76 infected individuals (Table 1), indicating that each had been sampled on average 212 
4.25 times (Table S3).  For bonobos, analysis of 146 fecal samples from three field sites 213 
identified 72 individuals (Table 1), indicating that each had been sampled on average 2.03 times 214 
(Table S4). Using these corrections, the proportion of SIVcpz infected chimpanzees was 215 
estimated for each sampling location, taking into account the number of unique mtDNA 216 
 
 
haplotypes as an indicator of the minimum number of chimpanzees tested.  From these 217 
determinations, prevalence rates were calculated (95% confidence limits were calculated based 218 
on binomial sampling).   219 
 220 
Full-length genome amplification.  The full-length genome of one representative 221 
SIVcpzPts strain from the DRC (BF1167) was sequenced as described (59, 78).  Briefly, 222 
partially overlapping subgenomic fragments were amplified from fecal RNA, gel purified, and 223 
sequenced directly. Chromatograms were examined for positions of base mixtures, and 224 
ambiguous sites were resolved as previously reported (7, 56, 73, 74).  For positions that did not 225 
affect the corresponding amino acid, the predominant nucleotide (highest amplitude in the 226 
sequence chromatogram or the most frequent nucleotide in repeat sequencing reactions) 227 
was chosen. For positions that affected the corresponding amino acid, the base that encoded 228 
the most common amino acid residue in alignments of existing SIVcpz protein sequences was 229 
selected. In the absence of an apparent common amino acid (e.g., in hypervariable protein 230 
regions), the nucleotide with the highest amplitude in sequence chromatograms was selected. 231 
Using these criteria, we were able to infer a unique consensus sequence for BF1167. 232 
 233 
Construction of a replication competent SIVcpzPts molecular clone.  To obtain a 234 
full-length infectious molecular clone of BF1167, the consensus sequence was chemically 235 
synthesized as three subgenomic fragments (Blue Heron Biotechnology). These included a 3.7 236 
kb 5’-LTR-pol fragment, a 3.9 kb pol-env fragment and a 2.3 kb env-3’-LTR fragment.  To 237 
facilitate subsequent cloning, unique MluI and ApaI sites were added to the 5’ and 3’ termini of 238 
the provirus, respectively.  These, together with internal NcoI and SalI sites at position 3,728 239 
and 7,596 were used to assemble the three subgenomic fragments to generate a full-length 240 
provirus. Ligation products were used to transform XL2-MRF bacteria (Stratagene). Resulting 241 
transformants were screened for appropriately sized inserts, transfected into 293T cells, and 242 
 
 
tested for infectivity in the TZM-bl assay (74) One functional clone (pBF1167) was identified and 243 
grown large scale (available from the National Institutes of Health Research and Reference 244 
Program, Rockville, MD). 245 
 246 
BF1167 infectivity and co-receptor usage. BF1167 as well as TAN2 (SIVcpz) and 247 
SG3 (HIV-1) reference clones were transfected into 293T cells and supernatants equilibrated by 248 
particle-associated RT activity as described (7, 74). Viral infectivity was assessed in TZM-bl 249 
cells, a HeLa-derived line which has been genetically-modified to constitutively express human 250 
CD4, CCR5 and CXCR4, and to contain integrated luciferase and β-galactosidase reporter 251 
genes under the control of an HIV-1 LTR (49, 84).  For co-receptor analysis, TZM-bl cells were 252 
seeded in 96 well plates at 8,300 cells/well overnight and then treated with the CCR5 antagonist 253 
TAK-779 (10μM), the CXCR4 antagonist AMD3100 (1.2μM), or a combination of both for one 254 
hour (74).  Virus was added in the presence of 40μg/ml DEAE-dextran and removed 48 hours 255 
later.  Cells were then lysed and analyzed for luciferase activity (Promega) using a Tropix 256 
luminometer with WinGlow version 1.24 software. 257 
 258 
CD4 T cell cultures.  Blood was obtained from normal human volunteers as well as 259 
healthy (SIV/HIV-1 uninfected) chimpanzees housed at the Yerkes Regional Primate Center as 260 
described previously (chimpanzee blood samples were left-over specimens from the annual 261 
health check-up) (14). Briefly, peripheral blood mononuclear cells were isolated using Ficoll 262 
Hypaque Plus (GE Healthcase).  CD4+ T cells were enriched using CD4 microbeads and 263 
magnetic cell sorting (Militenyi Biotec), stimulated with staphylococcal enterotoxin B (Sigma-264 
Aldridge) for 12 to 15 hours (3 μg/ml), and subsequently co-cultivated with autologous monocyte 265 
derived macrophages for optimal activation (14).  After 5 to 6 days, CD4+ T cells were removed 266 
from the macrophages, placed into DMEM with 10% FCS, and incubated with 30 U/ml 267 
 
 
interleukin-2 (IL-2).  After 24 hours, 5 x 105 CD4+ T cells were incubated with transfection-268 
derived viral stocks at a multiplicity of infection (MOI) of 0.1 (as determined on TZM-bl cells) in 269 
300μl DMEM containing 10% FCS and 30 U/ml IL-2 for 16 hours.  CD4+ T cells were washed 270 
three times, plated in 24-well plates in DMEM with 10% FCS and 30 U/ml IL-2, and reverse 271 
transcriptase activity was measured in culture supernatants every three days to monitor viral 272 
replication. 273 
 274 
Phylogenetic analyses. Partial pol (232 bp and 892 bp), vpu/env (481-514 bp), gp41 275 
(325-465 bp) and gp41/nef (699-1259 bp) sequences from the newly characterized viruses were 276 
aligned with HIV-1, SIVcpz and SIVgor reference sequences (GenBank accession numbers: 277 
HIV-1 group M: HXB2, K03455; HIV-1 group N: YBF30, AJ006022; HIV-1 group O: ANT70, 278 
L20587; HIV-1 group P: U14788, HQ179987; SIVcpzPtt: EK505, DQ373065; MB66, DQ373063; 279 
LB7, DQ373064 MT145, DQ373066; US, AF103818; CAM13, AY169968; GAB1, X52154; 280 
CAM3, AF115393; CAM5, AJ271369; SIVgor, FJ424866; SIVcpzPts: TAN1, AF447763; TAN2, 281 
DQ374657; TAN3, DQ373065; TAN5, JN091691 TAN13, JQ768416; UG38, JN091690; and 282 
ANT U42720) using CLUSTAL W (34). Regions of the sequences that could not be 283 
unambiguously aligned were removed from further analyses.  For SIVcpzBF1167, deduced 284 
Gag, Pol, Vif, and Env sequences were aligned with the corresponding protein sequences of the 285 
same HIV-1, SIVcpz and SIVgor reference strains. Gag/Pol and Pol/Vif protein overlaps were 286 
removed from the N- and C-termini of the deduced Pol protein sequences. In addition, the 287 
concatenated Pol and Vif alignment was divided into two regions around a previously reported 288 
recombination breakpoint (20, 68). Appropriate evolutionary models for phylogenetic analyses 289 
were selected using ModelTest version 3.7 (52) and ProtTest version 2.4 (1). For nucleotide 290 
sequence analyses these were K80+G for the diagnostic 232 bp pol fragment and GTR+I+G for 291 
the longer pol, vpu/env, gp41 and gp41/nef fragments. For amino acid sequence analyses the 292 
chosen models were LG+I+G (Gag), RtREV+I+G+F (Pol), LG+I+G+F (Pol/Vif) and WAG+I+G+F 293 
 
 
(Env).  Phylogenetic trees were constructed using maximum likelihood (22) and Bayesian (54) 294 
methods, the latter with a 25% burn in and using as a convergence criterion an average 295 
standard deviation of partition frequencies < 0.01. 296 
For species and subspecies analysis, mtDNA control region (D loop) sequences were 297 
aligned and identical sequences grouped into haplotypes (Table S2).  The evolutionary 298 
relationships of the new haplotypes to each other and references sequences from the database 299 
were then determined by phylogenetic analysis. A neighbor-joining tree is shown in Fig. S1. 300 
 301 
GenBank accession numbers. New SIVcpzPts sequences have been deposited in 302 
GenBank under accession numbers JQ866001, JQ866003-JQ866011, JQ866013-JQ866017, 303 
JQ866024, JQ866026-JQ866041, JQ866043-JQ866045, JQ866047-JQ866052, JQ866055, 304 
JQ866057-JQ866059, JQ866061-JQ866066, JQ866068-JQ866070 JX178444-JX178449; the 305 
new P. t. schweinfurthii and Pan paniscus mitochondrial D-loop sequences are listed in Table 306 





SIVcpz infection is endemic and widespread among eastern chimpanzees. To 312 
determine the geographic distribution and prevalence of SIVcpz in Democratic Republic of the 313 
Congo (DRC), we conducted a comprehensive, non-invasive (fecal based) survey at 41 different 314 
collection sites (Fig. 1B).   Between January 2001 and May 2011, we obtained a total of 2,480 315 
fecal samples north of the Congo River in an area spanning almost 250,000 km2.  Given the 316 
vastness of this study area, most samples were collected by local trackers in the vicinity of their 317 
villages.  While this led to some variation in sample quality, we were able to obtain samples as 318 
far south as Kasese (KE), as far east as Gombari (GO) and Walikale (WK), as far north as 319 
 
 
Bondo (BD) and Niangara (NI), and as far west as Kotakoli (KO) and Bumba (BU) (Fig. 1B).  320 
Except for four samples from pet chimpanzees, all other specimens were obtained from wild-321 
living apes within their natural habitat (Table 1). We also obtained samples from habituated P. t. 322 
schweinfurthii apes in the Budongo Forest (BG) (53) and the Kyambura Gorge (KY) in Uganda, 323 
and from a non-habituated group in the Gishwati Forest (GI) in Rwanda (50). The rationale for 324 
these surveys was to examine whether previous studies had missed isolated foci of SIVcpz 325 
infection in east Africa. Since the latter field sites were well-established, sample collection and 326 
storage occurred under more controlled conditions. 327 
Before testing for SIVcpz antibodies and nucleic acids, all specimens were subjected to 328 
mitochondrial (mt) DNA analysis to confirm their species origin and assess their integrity. This 329 
analysis identified 495 samples that were either not of chimpanzee origin, represented fecal 330 
mixtures from more than one individual, or were too degraded for further analysis (Table 1). The 331 
remaining 2,070 samples yielded mtDNA (D loop) sequences, which comprised 252 different 332 
haplotypes (Fig. S1).  All of these were subjected to enhanced chemiluminescence (ECL) 333 
Western blot analysis, a method that detects SIVcpz specific antibodies in fecal extracts with 334 
high sensitivity (0.92) and specificity (1.00) even after prolonged storage at ambient 335 
temperatures (30).  Consistent with previous findings, none of the samples collected in Uganda 336 
and Rwanda were SIVcpz antibody positive (Table 1).  Interestingly, however, 323 fecal 337 
specimens from 19 different sites in the DRC exhibited clear evidence of SIVcpz infection (Fig. 338 
2; Table 1).  All of these reacted strongly with the HIV-1 p24 core antigen, and 11%, 62% and 339 
35% also reacted with p17 Gag, reverse transcriptase (p66/p55) and integrase (p31) proteins, 340 
respectively.  Surprisingly, half of the samples (54%) also exhibited cross-reactivity with the 341 
HIV-1 envelope antigens (gp41, gp120, gp160), which in some cases was as strong as the 342 
human positive control (Fig. 2).   343 
To determine the number of SIVcpz infected apes at the 19 sampling locations, we 344 
subjected all antibody-positive samples to microsatellite analyses (Table S3). Many of these 345 
 
 
failed to yield a complete genotype, due to partial sample degradation. To guard against allelic 346 
drop out, we thus allowed mismatches at up to four microsatellite loci for samples that shared 347 
the same mtDNA haplotype. This conservative approach identified a total of 76 SIVcpz infected 348 
apes as a minimum estimate (Table 1).  Microsatellite analysis also provided a quantitative 349 
measure of redundant sampling, which together with the proportion of degraded specimens 350 
allowed us to calculate the prevalence of SIVcpz infection at each collection site.  As shown in 351 
Table 1, analysis of an estimated 567 eastern chimpanzees yielded an overall prevalence rate 352 
of 13.4% (95% confidence interval: 10.7% - 16.5%).  As previously observed in Cameroon and 353 
Tanzania, infection rates at individual field sites varied widely (Table 1), with high prevalence 354 
rates observed in some communities and low level or absence of infection in others. In general, 355 
evidence for infection was observed throughout the study area, indicating that SIVcpz was not 356 
restricted to any one geographic region.  The only exceptions were field sites in the northern 357 
part of the range, near the Uele River (BT, BD, AN, NI, DL, MA, PO, RU, IS), which seemed to 358 
be free of SIVcpz infection.  However, the number of usable samples from these sites was very 359 
small (n=77), representing only a minor fraction (3.7%) of the total survey.  Given this and the 360 
extent of sample degradation, it is thus possible that infected communities in this northern area 361 
were missed. Seven sites exhibited prevalence rates of 30% or higher, including in the far 362 
western (UB) and eastern (MU) parts of the DRC. These results indicate that SIVcpz is common 363 
and widespread among most P. t. schweinfurthii communities in the DRC (Fig. 1B), with 364 
prevalence rates similar to, or exceeding, those previously observed in P. t. troglodytes apes in 365 
Gabon and Cameroon (30, 36, 42, 78).   366 
 367 
No evidence of SIVcpz infection in wild-living bonobos.  In addition to eastern 368 
chimpanzees, the DRC is also home to bonobos (Pan paniscus), whose habitat is restricted to 369 
forest areas south of the Congo River (19).  Although a limited number of bonobos has 370 
previously been tested in captivity (77), wild-living members of this species have never been 371 
 
 
screened for SIVcpz infection.  To examine whether bonobos harbor SIV, we collected 543 fecal 372 
samples from six field sites located throughout the species range (Fig. 1B).  All of these were 373 
subjected to mtDNA analysis, which identified 48 degraded or misidentified samples.  The 374 
remaining 495 samples yielded mtDNA (D loop) sequences that grouped into 24 distinct 375 
haplotypes (Fig. S1).  These were tested by immunoblot analysis, which failed to detect SIV/HIV 376 
cross-reactive antibodies.  Western blots were completely negative for all samples, lacking even 377 
faint reactivity with the Gag p24 antigen, which is usually the most cross-reactive protein (Fig. 2). 378 
To estimate the number of sampled individuals, specimens from three field sites (IK, KR and 379 
LK) were genotyped at eight microsatellite loci (Table S4).  This analysis identified a minimum of 380 
72 individuals and an oversampling factor of 2.03.  From this and the proportion of degraded 381 
samples, we estimated to have screened approximately 244 individuals, none of whom was 382 
SIVcpz infected. 383 
 384 
SIVcpzPts strains form a monophyletic clade.  To examine the genetic relationships 385 
of the P. t. schweinfurthii viruses from the DRC to each other and previously characterized 386 
SIVcpz strains, all antibody positive samples were subjected to fecal RNA extraction and 387 
reverse transcription polymerase chain reaction (RT-PCR) amplification.  Using a diagnostic 388 
(minipol) primer set (Table S1), we amplified viral sequences from 75 antibody positive 389 
specimens.  Subsequent screening with gp41 and gp41/nef primers identified SIVcpz virion 390 
RNA in 17 additional samples, molecularly confirming infection in 25 of the 76 infected 391 
individuals (Table S3).  So as to not miss infection by other SIVs, we tested the remaining 392 
antibody positive samples using pan-SIV specific primers (Table S1).  No other sequences were 393 
amplified, indicating that the relatively low RT-PCR positivity rate (29%) was the result of partial 394 
sample degradation and not infection by other primate lentiviruses. All amplicons were 395 
sequenced and phylogenetically analyzed. Although the minipol sequences were relatively short 396 
(232 bp), they were of sufficient length to show that all of the new DRC viruses were members 397 
 
 
of the SIVcpzPts lineage.  As shown in Fig. 3, minipol sequences from 20 different individuals 398 
grouped with previously characterized P. t. schweinfurthii viruses in a clade supported by 399 
significant bootstrap values.   400 
To examine further the phylogenetic relationships of the newly derived SIVcpzPts strains, 401 
we targeted regions in pol (892 bp), vpu-env (419 bp), gp41 (405 bp) and gp41/nef (665 bp) for 402 
additional amplifications. Although longer sequences could only be amplified from 18 individuals, 403 
their phylogeny confirmed the minipol results (Fig. 4).  All newly derived sequences clustered 404 
according to their subspecies origin, forming a single well-supported viral lineage. In addition, 405 
the new SIVcpzPts strains exhibited evolutionary relationships similar to those previously 406 
described for SIVcpzPtt strains (30, 42, 78): viruses from distant collection sites generally 407 
formed well-separated clades or lineages, while viruses from the same geographic locale were 408 
usually closely related.  For example, viruses from Lubutu (LU) and Mungbere (MU) each 409 
formed discrete clusters, indicating local transmissions.  Significant clustering was also 410 
observed for viruses from Bongbola  (BL) and Mongandjo (MO), suggesting unimpeded virus 411 
flow between these neighboring sites.  Interestingly, the BL and MO strains were also closely 412 
related to SIVcpzANT, suggesting a possible geographic origin for this reference strain.  413 
Nonetheless, phylogeographic clustering was not uniform. Ape communities at Kabuka (KA) 414 
and Parisi (PA) harbored multiple divergent SIVcpzPts strains, perhaps indicating a greater 415 
connectivity of these communities. There was also evidence of recombination, as would be 416 
expected in populations co-infected with divergent viral lineages.  One strain from Parisi (PA1) 417 
had a mosaic genome as evidenced by its discordant clustering in pol and gp41/nef regions (Fig. 418 
4A and D). Importantly, however, there was no evidence of recombination between any of the 419 
newly identified DRC viruses and SIVcpzPtt strains.  In fact, none of the DRC viruses, including 420 
those identified at the western most collection sites (UB, BL, MO), were particularly closely 421 
related to P. t. troglodytes viruses.  Overall, SIVcpzPts strains were quite diverse, with 422 
 
 
nucleotide sequence distances of up to 25% and 35% in pol and gp41/nef regions, respectively, 423 
compared to 22% and 33% for members of the SIVcpzPtt group. 424 
To obtain at least one full-length SIVcpzPts sequence from the DRC, we selected a 425 
sample (BF1167) with a sufficiently high viral load for whole genome amplification.  Using strain 426 
specific primers, we amplified 12 partially overlapping fragments, which together comprised a 427 
complete proviral genome (Fig. 5A).  Inspection of the BF1167 consensus sequence revealed 428 
uninterrupted open reading frames for all structural and regulatory proteins as well as intact 429 
regulatory elements.  BF1167 also contained all previously identified SIVcpzPts signatures (56, 430 
59, 74), including three amino acid insertions in Gag p24 and a conserved PPLP Vif motif, a 431 
short Vpr protein of 95 amino acids, a 5 amino acid deletion at the C-terminus of Nef, and an 432 
insertion in the ectodomain of gp41.  Phylogenetic analysis of full-length Gag, Pol and Env 433 
proteins showed that BF1167 fell within the SIVcpzPts radiation (Fig. 6), confirming the 434 
relationships derived from the partial genome sequences. 435 
 436 
Generation of a replication competent SIVcpzPts clone. The genomic organization of 437 
BF1167 suggested that it may encode a replication competent provirus.  To test this, we 438 
synthesized its consensus sequence as three subgenomic fragments and ligated them into a 439 
low copy number vector (Fig. 5A).  The resulting plasmid clone was transfected into 293T cells 440 
and culture supernatant used to infect CD4+ T cell cultures. As shown in Fig. 5B, BF1167 441 
derived virus replicated efficiently and to high titers in CD4+ T cells from select human (n=4) 442 
and chimpanzee (n=4) donors, with kinetics similar to previously characterized SIVcpzPts 443 
(TAN2) and HIV-1 (SG3) strains. Testing its coreceptor usage, we found that the infectivity of 444 
BF1167 was completely blocked by the CCR5 antagonist TAK-779, but not by the CXCR4 445 
antagonist AMD3100 (Fig. 5C). This was also true for R5-tropic reference strains of HIV-1 (YU-446 
2), SIVcpzPts (TAN2) and SIVcpzPtt (MB897), but not for X4 (NL4-3) and R5/X4 dual tropic 447 
(WEAU) controls (Fig. 5C).  Taken together, these data indicate that the newly derived BF1167 448 
 
 
clone encodes an R5 tropic SIVcpzPts strain capable of infecting both primary human and 449 
chimpanzee CD4+ T cells. 450 
 451 
SIVcpzPts strains require more mutational steps than SIVcpzPtt strains to gain 452 
human-specific Gag matrix and Vpu adaptations. To evaluate the zoonotic potential of the 453 
newly derived DRC viruses, we compared their sequences in protein domains known to be 454 
under strong host specific selection pressure.  One such site was previously mapped to position 455 
30 (Gag-30) of the viral matrix protein (83).  Inspection of the proteome of all available SIVcpz 456 
and SIVgor strains identified a Met or Leu at this position. However, when these viruses infected 457 
humans, this residue was changed to an Arg in the inferred ancestors of HIV-1 groups M, N, 458 
and O, and subsequently to a Lys in some M, N and O strains (83). To determine the nature of 459 
Gag-30 in the DRC viruses, we amplified and sequenced the corresponding gag fragment from 460 
seven strains (Table S3). Interestingly, we found that two of the new viruses (MO1 and UB6) 461 
encoded a Met at Gag-30, similar to SIVcpzANT and all known SIVcpzPtt and SIVgor strains 462 
(Fig. 7).  However, the other five DRC strains encoded a Leu at Gag-30, similar to SIVcpzPts 463 
strains from Gombe (TAN) and Ugalla (UG). We then counted how many nucleotide 464 
substitutions would be required to change these Gag-30 codons to the HIV-1 specific residues. 465 
Arg is encoded by either CGN (N = A, C, T or G) or AGR (R = A or G), and Lys is encoded by 466 
AAR.  Thus, changing a Met (ATG) to Arg or Lys requires only a single nucleotide substitution. 467 
In contrast, Leu is encoded by CTN or TTR, and changing a Leu to Arg or Lys can therefore 468 
require one to three nucleotide substitutions (Fig. 7).  Examining the Gag-30 codon in all known 469 
SIVcpzPts strains, we found that 10 of 14 viruses, including four of seven DRC strains, encoded 470 
Leu using TTA or TTG codons and thus required at least two mutational steps to acquire the 471 
basic Arg or Lys residues at Gag-30 (Fig. 7). 472 
 Human specific adaptation has also shaped the function of the HIV-1 Vpu protein (18, 37, 473 
62). Vpu modulates the cell surface expression of a number of immunoregulatory proteins, 474 
 
 
including the CD4 receptor, the natural killer (NK) cell ligand NTB-A and the lipid antigen 475 
presenting protein CD1d (13, 41, 64). In HIV-1, Vpu also counteracts tetherin, an innate 476 
restriction factor that inhibits the release of nascent virus particles from infected cells by 477 
"tethering" them to the cell surface (43, 47, 76). In SIVcpz and SIVgor, Vpu lacks this function 478 
and these viruses antagonize tetherin via their Nef proteins (62). However, these same Nef 479 
proteins are inactive against human tetherin due to a five amino acid deletion that confers 480 
resistance (62). To gauge how difficult or easy it would be for the newly characterized DRC 481 
strains to acquire anti-human tetherin activity, we aligned their Vpu sequences, as well as those 482 
of available SIVcpzPtt or SIVgor strains, to the HIV-1 group M Vpu consensus sequence (Fig. 8). 483 
Focusing in particular on the N-terminal transmembrane domain (TMD), which has been shown 484 
to interact directly with tetherin via four amino acid residues on the same face of its membrane 485 
spanning helix (69), we counted the number of nucleotide substitutions that would be required to 486 
gain a functional A/GxxxAxxxAxxxW motif (15, 31, 69, 81, 82).  The results ranged from a single 487 
substitution for a subset of SIVcpzPtt strains to nine changes for the SIVcpzPts strain ANT, with 488 
the closest chimpanzee relatives of HIV-1 groups M (MB879, LB715) and N (EK505) requiring 489 
only one or two substitutions, respectively (Fig. 8).  Although the adaptive distance depended on 490 
the particular virus, SIVcpzPtt and SIVgor strains typically required fewer changes (median 4; 491 
range 1-8) than SIVcpzPts strains (median 7; range 3-9) to gain the helix-helix interaction motif, 492 
suggesting that they might be more prone to human adaptation. We also examined the 493 
cytoplasmic domains of the various Vpus for presence or absence of functional motifs that have 494 
previously been shown to play a role in tetherin trafficking and/or degradation, including a YxxΦ 495 
motif (57), a DSGxxS β−TrCP binding site (40) and a putative ExxxLV trafficking signal (33).  496 
Again, all of these domains were more commonly found in the Vpus of SIVcpzPtt and SIVgor 497 
strains than in the Vpus of SIVcpzPts strains (Fig. 8), with only one of 16 P. t. schweinfurthii 498 
viruses containing the ExxxLV motif that was recently shown to be required for efficient cell-free 499 
virion release from CD4 T cells (33). Thus, as a group, SIVcpzPts strains seem to require a 500 
 
 
much greater number of mutational steps to gain human specific adaptations than SIVcpzPtt 501 




Although long known to harbor SIVcpz in the wild (60, 61), wild-living eastern 506 
chimpanzees have not been thought to represent a virus reservoir. This is because previous 507 
field studies in Uganda, Rwanda and Tanzania failed to uncover infected apes at most locations, 508 
except for communities in Gombe National Park and the Masito-Ugalla region of western 509 
Tanzania (29, 55, 56, 60, 61, 67). However, since these areas of east Africa comprise only a 510 
small part of the P. t. schweinfurthii range (Fig. 1), we reasoned that the observed paucity of 511 
infections might not be representative of the entire subspecies.  To test this hypothesis, we 512 
targeted wild-living ape populations in the DRC, a country believed to be home to as many as 513 
200,000 P. t. schweinfurthii apes and 50,000 bonobos (10, 19). To cover this vast area, we 514 
recruited local teams of trackers to collect ape fecal samples in the vicinity of their villages.  515 
Although this resulted at times in prolonged sample storage at ambient temperatures and thus 516 
partial specimen degradation, we were able to procure an unprecedented number of specimens 517 
from a wide variety of different locales (Table 1). This allowed us to assess the prevalence and 518 
geographic distribution of SIVcpz throughout the Congo Basin and to determine whether wild-519 
living bonobos, which have not previously been tested for SIV infection, are natural carriers of 520 
this virus. We also screened additional communities in Uganda and Rwanda to determine 521 
whether isolated foci of SIVcpz infection had previously been missed. 522 
Testing 2,070 fecal samples from an estimated 567 P. t. schweinfurthii apes, we 523 
identified 323 specimens from 76 individuals to harbor SIVcpz specific antibodies, yielding an 524 
overall prevalence of 13.4% (95% confidence interval 10.7% - 16.5%).  Since chimpanzees in 525 
the northern DRC differ from their east African counterparts in a number of key behavioral traits 526 
 
 
(such as ground nesting and lack of termite fishing), which suggests a longstanding cultural 527 
separation (25), we also analyzed the DRC populations separately. Excluding samples from 528 
Rwanda and Uganda, we found that the remaining sites exhibited a prevalence of 14.9%.  529 
Remarkably, this estimate is 2.5 times higher than the prevalence previously determined for P. t. 530 
troglodytes ape in Cameroon (42).  In the latter study, analysis of 1,217 fecal samples from 25 531 
different field sites south of the Sanaga River yielded an overall prevalence of 5.9% (95% 532 
confidence interval 4.3% - 7.9%).  Although infected apes were identified at 10 of the 25 field 533 
sites, local infection levels were relatively low (42).  Only one Cameroonian site exhibited a 534 
prevalence of greater than 30% (42), compared to seven such sites in the DRC (Table 1). Since 535 
the methods of fecal collection and diagnosing SIVcpz were very similar, the observed 536 
differences cannot to be explained by ascertainment biases or technical differences.  Moreover, 537 
infection rates in the DRC represent minimum estimates given that many samples were partially 538 
degraded. Although SIVcpz is generally unevenly distributed among wild-living chimpanzees (29, 539 
36, 56, 60), our data indicate that P. t. schweinfurthii apes are at least as widely and commonly 540 
infected as P. t. troglodytes apes. A recent study of wild-living P. t. troglodytes apes in Gabon 541 
confirmed this, identifying SIVcpz infection at only three of ten locations, with high level infection 542 
detected at only one of these sites (36). In contrast, the newly screened communities in the 543 
Budongo Reserve (BG), the Kyambura Gorge (KY) and the Gishwati Forest (GI) were all virus 544 
negative, further supporting the notion that SIVcpz is absent from the extreme eastern edge of 545 
the P. t. schweinfurthii range, except for isolated communities in western Tanzania.  It remains 546 
unknown whether SIVcpz was once present there and has subsequently gone extinct, or 547 
whether its eastward spread was obstructed by habitat loss and/or other barriers, such that 548 
certain communities were never exposed.   549 
In contrast to eastern chimpanzees, none of 495 bonobo samples from an estimated 244 550 
individuals were SIV antibody positive (Table 1).  Although bonobos were sampled at fewer 551 
locations than P. t. schweinfurthii apes, the six field sites were widely distributed throughout the 552 
 
 
bonobo range (Fig. 1B).  Moreover, for all but one field site (BJ) significant numbers of samples 553 
were tested (Table 1), arguing against the possibility that low level infections were missed. 554 
There were also no differences in the way bonobo samples were collected, stored and 555 
transported compared to those from eastern chimpanzees.  Thus, sample degradation cannot 556 
be invoked as an explanation for the negative Western blot results. Based on these data, it 557 
seems likely that bonobos are free of SIVcpz infection. This is consistent with a previous study 558 
that failed to detect SIVcpz antibodies in the blood of 26 captive bonobos (77).  It is also 559 
consistent with the fact that bonobos and eastern chimpanzees have non-overlapping habitats 560 
(Fig. 1). However, given that western gorillas are only rarely infected with SIVgor (42), it will be 561 
important to exclude isolated infections of bonobos by testing additional individuals from a wider 562 
range of locations. It should also be noted that bonobos, like chimpanzees, are exposed to a 563 
variety of SIVs because they hunt and eat smaller primates, including different species of 564 
guenons (71, 72), which carry their own types of SIV (2). These monkey SIVs are genetically 565 
quite divergent from HIV-1/SIVcpz and may elicit antibodies that do not cross-react with HIV-1 566 
proteins (2, 44).  It will thus be important to include additional SIV antigens into future non-567 
invasive screening approaches to examine whether bonobos harbor such viruses. 568 
Previous evolutionary studies have shown that SIVcpz sequences form two highly 569 
divergent lineages, SIVcpzPtt and SIVcpzPts, according to their subspecies of origin (65-67) 570 
These studies also revealed that all groups of HIV-1 as well as SIVgor cluster within the 571 
SIVcpzPtt lineage, thus identifying P. t. troglodytes apes as the original source of both human 572 
and gorilla viruses (24, 48, 73, 79).  However, except for ANT (80) and the only partially 573 
characterized DRC1 virus (85), all other SIVcpzPts strains were derived from infected apes in 574 
Gombe and Ugalla (29, 55, 56), thus leaving the evolutionary history of viruses from the 575 
remaining parts of the P. t. schweinfurthii range open to question (46). In this study, we tested 576 
all antibody positive fecal samples from the DRC for the presence of SIVcpz sequences.  Using 577 
gag, pol, vpu and env primers, we were able to amplify virion RNA from 25 of the 76 infected 578 
 
 
individuals (Table S3).  Although this recovery rate was lower than in previous field studies, we 579 
obtained SIVcpz sequences from 14 of the 19 positive locations (Fig. 1B).  Importantly, we 580 
found that all of the new viruses clustered with previously characterized SIVcpzPts strains in all 581 
genomic regions analyzed (Figs. 3, 4 and 6). While some grouped according to their field site of 582 
origin, phylogeographic clustering seemed less pronounced in the DRC than previously 583 
observed in Cameroon (30, 78).  This may be because the largely contiguous forests in the 584 
DRC have provided for greater connectivity and thus exchange of divergent viruses over longer 585 
distances.  Nonetheless, all DRC viruses fell within the SIVcpzPts radiation, forming a single 586 
well supported phylogenetic lineage that also included viruses from Gombe and Ugalla (Figs. 3, 587 
4 and 6). This strict subspecies specific clustering indicates that P. t. schweinfurthii apes have 588 
been effectively isolated from P. t. troglodytes apes for a considerable period of time.  It also 589 
confirms that chimpanzees in the DRC were not the source of any known strain of HIV-1 (85).  590 
Given that SIVcpz infection rates in wild-living chimpanzees in the DRC are at least as 591 
high, if not higher, than in Cameroon and Gabon, it seems striking that SIVcpzPts strains have 592 
never been found in humans.  There are at least three potential explanations, which are not 593 
mutually exclusive:  One possibility is that humans in the DRC are less frequently exposed to 594 
SIVcpz.  Although it remains unknown exactly how humans acquired the ape precursors of HIV-595 
1 groups M, N, O and P, cross-species transmission must have occurred through cutaneous or 596 
mucous membrane exposure to infected ape blood and/or body fluids, which occurs most 597 
frequently in the context of bushmeat hunting (24). While firm data concerning the frequencies 598 
and types of human-ape interactions in the DRC are lacking, it is believed that hunting varies 599 
regionally due to differences in local traditions and preferences, with some tribes having taboos 600 
against the consumption of apes (46). Thus, human exposure to SIVcpz may have historically 601 
been lower in the DRC compared to west central Africa and this may explain the lack of 602 
SIVcpzPts zoonoses.  However, even if this were the case, this barrier is clearly no longer in 603 
place.  Bushmeat hunting in the DRC, including the poaching of chimpanzees, has been on the 604 
 
 
rise in the past decade due to political turmoil and economic changes (5).  A recent study of 605 
apes north and south of the Uele River documented a major increase in chimpanzee killing due 606 
to an influx of artisanal diamond and gold miners (26). Thus, increased surveillance of humans 607 
in these areas for SIVcpzPts and other ape-derived infections may be warranted (6, 11, 39).  608 
A second explanation is that SIVcpzPts infections of humans may in fact have occurred, 609 
but gone unrecognized, because of limited human sampling and a lack of specific tests. The 610 
great majority of HIV-1 infections in the DRC and elsewhere are diagnosed serologically, using 611 
enzyme-linked immunosorbent assays (ELISA) or rapid test immunoblot approaches. Despite 612 
their genetic diversity, many of the ape infections characterized here exhibited a Western blot 613 
profile indistinguishable from that of the positive HIV-1 control (Fig. 2).  It is thus possible that a 614 
human infected with such a virus could be misdiagnosed as being infected by HIV-1 group M, 615 
especially since the vast majority of HIV-1 infections in the DRC are not molecularly confirmed. 616 
However, such SIVcpzPts zoonoses -- if they have indeed occurred -- are unlikely to have 617 
infected large numbers of people, because more substantive outbreaks would likely have been 618 
detected by existing surveillance programs, such as those that discovered the very rare N and P 619 
groups of HIV-1 (48, 68). The apparent lack of SIVcpzPts zoonoses could also reflect regional 620 
differences in human transmission networks, since sporadic introductions into less dense, less 621 
urban and/or less well connected populations would be more likely to result in dead-end 622 
infections. 623 
A third possibility is that SIVcpzPts strains face greater adaptive hurdles before they can 624 
replicate and spread efficiently in the human host.  Examining SIVcpz proteomes for amino 625 
acids that were highly conserved in the ape precursors of HIV-1, but changed each time these 626 
viruses crossed the species barrier to humans, we previously found a Met or Leu in all 627 
SIVcpz/SIVgor strains, but an Arg in the inferred ancestors of HIV-1 groups M, N, and O, and a 628 
Lys in some HIV-1 strains (83). We also showed that changing Met/Leu at Gag-30 to Arg/Lys 629 
greatly enhanced the replication fitness of SIVcpz strains in human tonsil cultures, while the 630 
 
 
opposite was true for HIV-1 strains that contained the ape-specific Gag-30 residues (7).  These 631 
studies provided compelling evidence that host specific adaptation at Gag-30 is required for 632 
efficient replication of SIVcpz in human lymphatic tissue. When we determined the nature of the 633 
Gag-30 residue in all available SIVcpzPts strains, including the new viruses from the DRC, we 634 
found that most require twice as many mutational steps than SIVcpzPtt and SIVgor strains to 635 
adapt at Gag-30 (Fig. 7). Substantial adaptive hurdles were also identified for the SIVcpz Vpu 636 
protein (18, 37, 62). It has been shown that upon cross-species transmission, the ape 637 
precursors of HIV-1 had to switch from Nef- to Vpu-mediated tetherin antagonism (37, 62). 638 
However, only the pandemic M group viruses acquired efficient anti-tetherin activity, while the 639 
much less prevalent group N, O and P viruses either failed to gain this activity or lost other Vpu 640 
functions (37, 62, 63, 82, 86, 87). These findings have been taken to indicate that successful 641 
SIV zoonoses require effective tetherin antagonism (23).  When we compared ape virus Vpu 642 
sequences to that of the HIV-1 group M consensus, we found that some SIVcpzPtt Vpus 643 
required only very few changes to gain key functional motifs (Fig. 8).  In contrast, most 644 
SIVcpzPts Vpus required a substantially larger number of substitutions to acquire these same 645 
human specific signatures (Fig. 8).  Although counting numbers of mutational steps represents a 646 
gross oversimplification of the adaptation process, our analyses suggest that certain SIVcpzPtt 647 
strains are better equipped to become new human pathogens than most SIVcpzPts strains. The 648 
fact that the reconstructed BF1167 genome (as well as other SIVcpzPts strains) replicates well 649 
in human CD4+ T cells (Fig. 5) does not argue against this, since such maximally stimulated 650 
cultures do not accurately recapitulate the conditions of viral replication and transmission in vivo 651 
(7). 652 
In summary, we report here that wild-living P. t. schweinfurthii populations are much 653 
more widely and commonly infected with SIVcpz than previously appreciated. This is particularly 654 
true for communities in the northern DRC, which represent a large continuous population that 655 
seems to provide opportunity for virus flow across vast areas.  Whether these viruses have a 656 
 
 
reduced potential to infect humans and cause epidemic outbreaks is not known, but should be 657 
investigated.  In particular, studies of host restriction mechanisms that may have prevented the 658 
spread of these viruses in the human population would be informative.   This is now possible, 659 
since well-characterized reagents, including a large panel of SIVcpzPtt and SIVcpzPts infectious 660 
molecular clones, are available for study. The high prevalence of SIVcpzPts infection also has 661 
implications for conservation efforts. SIVcpz is quite pathogenic and has been shown to 662 
negatively impact chimpanzee population growth (17, 29, 55, 75). Given that the DRC is home 663 
to half of the world’s remaining chimpanzees, it will be critical to determine in much greater 664 
detail to what extent SIVcpz has penetrated these populations, such that the impact of this 665 
infection on the long-term survival of this species can be determined.  Finer grained prevalence 666 
and natural history data will also be critical for attempts to limit the spread of SIVcpz in wild ape 667 
populations, for example through the use of adeno-associated virus (AAV) mediated gene 668 
transfer of antibodies that neutralize SIVcpz as a prophylactic or therapeutic vaccine (4, 27), 669 
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 1007 
FIGURE LEGENDS 1008 
 1009 
FIG 1 Location of ape study sites. (A) Geographic ranges of chimpanzees (Pan troglodytes) and 1010 
bonobos (Pan paniscus) in sub-Saharan Africa. The four recognized chimpanzee subspecies 1011 
are color-coded (P. t. verus, grey; P. t. ellioti; magenta; P. t. troglodytes; blue; P. t. schweinfurthii, 1012 
yellow).  International borders, major rivers and lakes, and select cities are shown.  Asterisks 1013 
 
 
indicate where the closest SIVcpz relatives of HIV-1 groups M (red) and N (green) were 1014 
identified in wild-living P. t. troglodytes communities (30).  A box outlines the study area, which 1015 
is magnified in panel B.  (B) Location of chimpanzee (circles) and bonobo (squares) study sites 1016 
in the DRC, Uganda and Rwanda.  The ranges of eastern chimpanzees (yellow) and bonobos 1017 
(orange) are shown as in (A). Sites where SIVcpz was detected are indicated in red, with white 1018 
and yellow lettering denoting the recovery of antibody positive versus antibody and nucleic acid 1019 
positive samples, respectively. Previously published SIVcpz positive and negative sites in 1020 
Uganda, Rwanda and Tanzania are shown in dark red and gray, respectively  (GM, Gombe 1021 
National Park; UG, Masito-Ugalla region). Forested areas are shown in green, while arid and 1022 
semi-arid areas are in yellow and brown. Major lakes are shown in black with major rivers 1023 
depicted in blue. Dashed white lines indicate national boundaries.  1024 
 1025 
FIG 2 Detection of SIVcpz antibodies in chimpanzee fecal samples. Fecal samples from eastern 1026 
chimpanzees (middle) and bonobos (right) as well as human controls (left) were tested by 1027 
enhanced chemiluminescent Western blot using HIV-1 antigen containing strips. Samples are 1028 
numbered, with letters indicating their collection site as shown in Fig. 1B. Molecular weights of 1029 
HIV-1 proteins are indicated. The banding pattern of plasma from HIV-1 infected (positive) and 1030 
uninfected (negative) humans are shown for control.  1031 
 1032 
FIG 3 SIVcpz strains from the DRC cluster according to their subspecies of origin. A maximum 1033 
likelihood tree was constructed from partial (232 bp) pol sequences (spanning HXB2 1034 
coordinates 4682 – 4913). Newly characterized SIVcpz strains from the DRC are highlighted, 1035 
with sequences from the same individual color-coded (for individual designation and sample 1036 
numbers see Table S3). Previously characterized SIVcpz, SIVgor and HIV-1 strains forming the 1037 
SIVcpzPtt (top cluster) and SIVcpzPts (bottom cluster) lineages are shown in black.  The latter 1038 
include reference strains from Gombe (TAN1, TAN2, TAN3, TAN5, TAN13) and Ugalla (UG38), 1039 
 
 
as well as ANT, which is of unknown origin. Asterisks indicate bootstrap support ≥ 70%. The 1040 
scale bar represents 0.05 substitutions per site. 1041 
 1042 
FIG 4 Phylogeny of SIVcpz in the DRC. Maximum likelihood trees were constructed of partial 1043 
(A) pol (HXB2 coordinates 3887 – 4778, (B) vpu/env (HXB2 coordinates 6062 – 6578), (C) gp41 1044 
(HXB2 coordinates 7836 – 8264, and gp41/nef (HXB2 coordinates 8277 – 9047) sequences. 1045 
Regions of ambiguous alignment were removed from this analysis. New SIVcpzPts strains from 1046 
the DRC are show in blue, followed by the sample code in parentheses. Previously 1047 
characterized SIVcpz, SIVgor and HIV-1 strains forming the SIVcpzPtt (top cluster) and 1048 
SIVcpzPts (bottom cluster) lineages are shown in black. Nodes with both bootstrap support ≥ 1049 
70% and Bayesian posterior probability ≥ 0.95 are indicated by asterisks. Scale bar represents 1050 
0.05 substitutions/site. 1051 
 1052 
FIG 5 Generation and biological characterization of a replication competent SIVcpzPts 1053 
molecular clone. (A) Individual RT-PCR amplicons (orange boxes) of BF1167 are shown in 1054 
relation to the SIVcpz genome. Fragments are drawn to scale, with nucleotide sequences 1055 
numbered starting at the beginning of the R region in the 5’ LTR (see scale bar). Three 1056 
subgenomic fragments bound by MluI, NcoI, SalI, and ApaI restriction sites were synthesized 1057 
and then assembled to produce a full-length provirus (blue line). (B) The replication kinetics of 1058 
BF1167 derived virus in human (top) and chimpanzee (bottom) CD4+ T-cells is shown in 1059 
relation to HIV-1 (SG3, blue) and SIVcpzPts (TAN2, green) reference strains (x-axis: days post 1060 
infection; y-axis nanogram of reverse transcriptase (RT) activity per ml of culture supernatant). 1061 
Average values (and one standard deviation) from different experiments (indicated in 1062 
parentheses) are shown. (C) TZM-bl cells were pretreated with AMD3100 (inhibitor of CXCR4), 1063 
TAK779 (inhibitor of CCR5), or both prior to addition of the virus preparations indicated.  Virus 1064 
infectivity is plotted on the vertical axis as a percentage of the untreated control.  Virus derived 1065 
 
 
from reference clones NL4.3 (X4-tropic), YU2 (R5-tropic), and WEAU1.6 (dual tropic) as well as 1066 
SIVcpzPtt (MB897) and SIVcpzPts (TAN2) strains were included for control. BF1167 is an R5-1067 
tropic virus. 1068 
 1069 
FIG 6 Evolutionary relationships of BF1167 full-length genome sequences. Maximum likelihood 1070 
trees were inferred from amino acid (AA) sequence alignments of the major proteins, including 1071 
(A) Gag (420 AA; HXB2 coordinates 790 – 2280), (B) N-terminal Pol (630 AA; HXB2 1072 
coordinates 2295 – 4184), (C) C-terminal Pol/Vif (453 AA; HXB2 coordinates 4185 – 5556), and 1073 
(D) Env (729 AA; HXB2 coordinates 6324 – 8792); the Pol protein was separated into two 1074 
fragments at a point where a recombination breakpoint was previously identified in HIV-1 group 1075 
N. The BF1167 sequence is shown in blue. Previously characterized SIVcpz, SIVgor and HIV-1 1076 
strains forming the SIVcpzPtt (top cluster) and SIVcpzPts (bottom cluster) lineages are shown in 1077 
black. Nodes with both bootstrap support ≥ 70% and Bayesian posterior probability ≥ 0.95 are 1078 
indicated by asterisks. Scale bar represents 0.05 amino acid replacements/site. 1079 
 1080 
FIG 7 Adaptive requirements of SIVcpz at Gag-30. The codon at position 30 of the Gag matrix 1081 
protein is shown for 14 SIVcpzPts strains, including seven new viruses from the DRC. Ten of 1082 
these 14 viruses encoded a Leu using TTA or TTG codons at Gag-30, which require at least two 1083 
nucleotide changes to become Arg (CGN or AGR) or Lys (AAR) codons.  In contrast, all 1084 
sequenced SIVcpzPtt (n=15) and SIVgor (n=3) strains contain a Met ATG codon, which requires 1085 
only a single substitution to change to either human specific signature. 1086 
 1087 
FIG 8 Adaptive requirements of SIVcpz in transmembrane and cytoplasmic domains of Vpu. 1088 
Vpu amino acid sequences of SIVcpzPtt, SIVgor and SIVcpzPts strains are aligned in their 1089 
transmembrane domain to the corresponding region of the HIV-1 group M consensus as 1090 
previously described (37). Dashes indicate gaps introduced to optimize the alignment. Gray 1091 
 
 
boxes highlight residues of a conserved helix-helix interaction motif (G/AxxxAxxxAxxxW; where 1092 
‘x’ may be any amino acid) that is required to counteract human tetherin (69, 81). The minimum 1093 
number of mutational steps needed to change the corresponding amino acid to that of the 1094 
human residue is indicated on the right.  Columns on the far right indicate the presence (+) or 1095 
absence (blank) of previously described transport and/or degradation motifs in the intracellular 1096 
domain of Vpu. These include a YxxΦ motif scored as Yxx(L/M/V/I/F/W) (8, 21, 57), a β-TrCP 1097 
ubiquitin-dependent degradation signal scored as D(S/D/E)Gxx(S/D/E) (28, 40), and a putative 1098 
trafficking signal scored as (D/E)xxxL(L/V/I/M) (33). 1099 








































AM DRC P.t.s. 44 37 0.16 n/a 5 15 3 3 33 2-43 
AN DRC P.t.s. 16 15 0.06 n/a 1 0 0 0 0 0-60 
AZ DRC P.t.s. 6 5 0.17 3 2 4 2 0 67 9-99 
BA DRC P.t.s. 256 229 0.11 n/a 22 39 5 1 9 3-20 
BD DRC P.t.s. 15 15 0.00 n/a 9 0 0 0 0 0-34 
BE DRC P.t.s. 134 87 0.35 n/a 18 0 0 0 0 0-17 
BF DRC P.t.s. 42 37 0.12 n/a 7 12 1 12 11 0-48 
BI DRC P.t.s. 124 103 0.17 n/a 14 0 0 0 0 0-14 
BL DRC P.t.s. 50 48 0.04 n/a 21 3 2 2 10 1-30 
BM DRC P.t.s. 47 43 0.09 n/a 2 0 0 0 0 0-31 
BR DRC P.t.s. 59 59 0.00 n/a 1 0 0 0 0 0-23 
BS DRC P.t.s. 20 10 0.50 n/a 8 0 0 0 0 0-37 
BT DRC P.t.s. 5 4 0.20 n/a 4 0 0 0 0 0-60 
BU8 DRC P.t.s. 18 1 0.00 n/a 1 1 1 0 100 3-100 
DL DRC P.t.s. 5 5 0.00 n/a 1 0 0 0 0 0-98 
EP DRC P.t.s. 160 126 0.21 n/a 19 7 2 4 7 1-22 
GO DRC P.t.s. 5 2 0.60 n/a 2 0 0 0 0 0-84 
IJ DRC P.t.s. 27 7 0.74 n/a 2 0 0 0 0 0-84 
IS DRC P.t.s. 5 4 0.20 n/a 3 0 0 0 0 0-71 
KA DRC P.t.s. 164 126 0.23 n/a 23 33 13 10 43 25-63 
KE DRC P.t.s. 15 7 0.53 n/a 3 0 0 0 0 0-71 
KO DRC P.t.s. 90 78 0.13 n/a 12 9 1 0 6 0-27 
KS9 DRC P.t.s. 139 11 0.15 n/a 8 4 3 0 38 9-76 
LU DRC P.t.s. 212 163 0.23 n/a 18 34 3 27 8 2-21 
MA DRC P.t.s. 11 7 0.36 n/a 1 0 0 0 0 0-84 
MN DRC P.t.s. 2 1 0.50 n/a 1 0 0 0 0 0-98 
MO DRC P.t.s. 21 15 0.29 n/a 10 2 1 2 10 0-45 
MU DRC P.t.s. 58 53 0.09 n/a 11 26 6 3 50 21-79 
NI DRC P.t.s. 7 4 0.43 n/a 2 0 0 0 0 0-84 
ON DRC P.t.s. 59 40 0.32 n/a 4 0 0 0 0 0-34 
OP DRC P.t.s. 85 61 0.28 n/a 9 26 2 18 14 2-43 
PA DRC P.t.s. 131 110 0.16 n/a 16 48 12 5 46 27-67 
PO DRC P.t.s. 11 10 0.09 n/a 6 0 0 0 0 0-46 
RU DRC P.t.s. 18 13 0.28 n/a 4 0 0 0 0 0-60 
UB DRC P.t.s. 117 99 0.15 n/a 23 11 7 3 30 13-53 
UD DRC P.t.s. 5 5 0.00 n/a 2 0 0 0 0 0-84 
UM DRC P.t.s. 100 61 0.39 n/a 10 0 0 0 0 0-23 
WA DRC P.t.s. 170 151 0.11 n/a 25 40 8 1 22 10-39 
WB DRC P.t.s. 91 69 0.24 n/a 11 8 3 1 19 4-46 
WK DRC P.t.s. 35 33 0.06 n/a 10 0 0 0 0 0-31 
WL DRC P.t.s. 44 39 0.11 n/a 13 1 1 0 8 0-36 
BG Uganda P.t.s. 20 19 0.05 19 9 0 0 0 0 n/a 
KY Uganda P.t.s. 16 16 0.00 13 4 0 0 0 0 n/a 
GI Rwanda P.t.s. 49 42 0.14 n/a 6 0 0 0 0 0-31 
n=44   2,565 2,070 0.19 56710 383 323 76 92 13.4 10.7-16.5 
BJ DRC P.p. 2 2 0 n/a 1 0 0 0 0 0-98 
BN DRC P.p. 96 85 0.12 n/a 7 0 0 0 0 0-8 
IK DRC P.p. 56 39 0.30 17 7 0 0 0 0 0-20 
KR DRC P.p. 78 69 0.12 38 12 0 0 0 0 0-9 
LK DRC P.p. 43 38 0.12 17 8 0 0 0 0 0-20 
ML DRC P.p. 268 262 0.02 n/a 6 0 0 0 0 0-3 
n=6   543 495 0.09 24410 41 0 0 0 0 0-1.5 
1Field sites are designated by a two-letter code (their location is shown in Figure 1). 
2DRC, Democratic Republic of the Congo. 
3P.t.s., Pan troglodytes schweinfurthii; P.p., Pan paniscus. 
4Chimpanzees at the BG and KY field sites were individually known; For the AZ, IK, KR and LK field sites, the number of sampled apes was determined by 
microsatellite analyses (Table S4); n/a; not available. 
5Minimum number of individuals as indicated by the number of distinct mtDNA haplotypes. 
6SIVcpz infected chimpanzees were enumerated for each field site by microsatellite analysis of antibody positive fecal samples (Table S3). 
7Prevalence of SIVcpz infection (%) with 95% confidence intervals; values are based on the proportion of SIVcpz antibody positive fecal samples, corrected 
for sample degradation and oversampling. 
8The single sample from the BU field site was collected from a pet chimpanzee. 
9Samples from the KS field site include three from pet chimpanzees. 






































































































































































































































































































































































































































































































































































































































































































































































































































Strain Gag-30 Arg Lys
SIVcpzPts
BF1167 Leu CTT 1 3
KA1 Leu TTA 2 2
LU2 Leu TTG 2 2
MO1 Met ATG 1 1
OP2 Leu TTG 2 2
PA1 Leu TTG 2 2
UB6 Met ATG 1 1
ANT Met ATG 1 1
TAN1 Leu TTA 2 2
TAN2 Leu TTA 2 2
TAN3 Leu TTA 2 2
TAN5 Leu TTG 2 2
TAN13 Leu TTA 2 2
UG38 Leu TTG 2 2
SIVcpzPtt Met ATG 1 1
(n = 15)




HIV-1 M M Q P L - - - - - E I L A I V L V V A L I I A I V V T I V F I
CAM3 M L T W - - - - - E Q I G L I I G I I I I I V A G I A F K
DP943 M L T W - - - - - E Q I G L I L G I G I I T V V G I A F I
MB897 M E I F - - - - - I I L G L I I V I L V I I V V L K A Y E
LB715 M T G L - - - - - E I I G L I I V I L S I I G A I V A Y N
CAM5 M L I W - - - - - E Q I G L I L G I L I I I V V G I A Y K
EK505 M L L L - - - - - I K L G F I L A I T L I I V V A I V Y R
LB7 M D L I - - - - - - E L G L I L V I L I I I V V L K A Y Q
US M L N W - - - - - F E I G L I L G I G I L V I I G L V A R
MB66 M D I V Q - - - - Q V G L L V L I I L V I I V I V K V Y K
GAB2 M L S M - - - - W V A I G L I I G T L V I I V V G I V G I
MT145 M Q L E - - - - - - I V L I I F I A M L V I F A I A A Y K
CAM155 M H L - - - - - - - - V Y L I S I I I L L I V V S K V W I
CAM13 M I L I - - - A L G C L A I A I L L I F I R N L R L C K Q
GAB4 M Q L D N A A I H F L A L I V I I E G V I G A C WG Y T Q
GAB1 M T L L - - - - - V G L V L I V G L A W N C I W Y I I K W
BQ664 M H S R - - - - - E I A A I I G S I L A V V V L V K I W L
CP2135 M H P R - - - - - D I I V I I G I T L A A V I V L K A L A
CP2139 M H P R - - - - - D I I V I I G I T L A V V I I L K I F A
CP684 M H P R - - - - - D I L V I I G I I L A V V I S L K A L A
BF1167 M L - - - - - - - WQ F L QW Q Y L WG G I V I I I A L L
TAN3 M V K I V V G S V L T N V I G F C I L I L G G G L I I A F
TAN13 M I K V V V G N L E Q N V V G L V I I V L V G G G L I A W I
OP2 M T P T - - - - - E V G V A A A A V W I I I V V I K A K R
TAN1 M I K I V V G S V S T N V I G L C I L I L G G G L I G I G
BL1 M T Q V - - - - G E Y C F L A A I L W I I I I I I K A L E
KA1 M Q I S D S - - D L I C V L I S L I V I L I L I V A G V I
MO1 M P L V - - - - G E Y C L L A A I L W I I L I I V L V R R
LU2 M Q Y W - - - - - E G E L L L A I S W V L I F I Y K S I Q
LU1 M Q Y W - - - - - E G E L L L A T S W V L I F I Y K S I Q
TAN5 M V K L V V G S L L T N V I G F C I L I L G G S L I V I I
UG31 M R L V V - G S F M Q N V L G L F I V V I G G G L I GW V
TAN2 M V K L V V G S V L T N V I G F C I L I L G G G L I I T I
UG38 M R L V G - G S I I Q N V V G L F I V V I G G G L I GWG
PA1 M Q K I - - - - D N I E L V I F A I W S A S V I L L I A W
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